FDA names former pharmaceutical company executive to oversee US drug program
FDA Commissioner Marty Makary announced that Dr. George Tidmarsh, a cancer and pediatric specialist, will direct the agency's Center for Drug Evaluation and Research, which regulates the safety and effectiveness of all U.S. drugs.
His appointment comes a month after the center's acting director, Dr. Jacqueline Corrigan-Curay, announced her retirement.
As the agency's top drug regulator, Tidmarsh will be charged with following through on a number of commitments made by Makary and his boss, Health Secretary Robert F. Kennedy Jr., including reviewing the safety of the abortion pill mifepristone. The FDA is also scrutinizing certain uses of other long-established drugs, including antidepressants and hormone-replacement drugs for menopause.
Tidmarsh founded and led several pharmaceutical companies, including Horizon Pharmaceuticals, maker of an anti-inflammatory medication for arthritis. He has also served as an adjunct professor at Stanford University.
The FDA's drug center is the agency's largest unit, with nearly 6,000 staffers responsible for reviewing the safety and effectiveness of new drugs and monitoring the use and marketing of older drugs.
About 2,000 FDA staffers have been laid off as part of widescale cuts to the federal health workforce overseen by Kennedy. More than 1,000 others have taken buyouts or early retirement, while many others are reportedly searching for new jobs. The departures have threatened basic FDA operations, including the timely review of new drugs.
FDA's drug center hasn't had a permanent director since January, when Dr. Patrizia Cavazzoni stepped down days before President Donald Trump took office.
Nearly all of the FDA's senior leadership positions have turned over in recent months, either due to retirements, resignations or actions by administration officials placing them on administrative leave.
FDA center directors typically hold their positions for years or even decades, serving across multiple administrations, whether Republican or Democrat.
In May, Makary named Dr. Vinay Prasad, a prominent critic of the FDA's COVID response, to run the agency's vaccine center. He was also named to the post of FDA chief medical officer. Prasad joined the agency after his predecessor, longtime vaccine chief Dr. Peter Marks, was forced out in March.
The head of FDA's tobacco center was also forced to step down in April. A permanent replacement has not yet been named.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
11 minutes ago
- CNN
100 days into the job, FDA Commissioner talks to CNN about staff changes, agency process— and Coke's switch to sugar
Federal agencies Food & health FacebookTweetLink The US Food and Drug Administration is plowing ahead with sweeping plans to crack down on ultra processed foods and reshape the way new drugs and devices are reviewed and approved, the agency's commissioner, Marty Makary, told CNN in an interview this week. Makary sat down with CNN at the FDA's White Oak, Maryland campus, roughly 100 days into his tenure as the head of the agency that oversees vast portions of the US's food and health system: drugs, medical devices, tobacco and a portion of the food supply that accounts for roughly a fifth of the US economy. In the large, sunny room overlooking the courtyard at the center of the FDA's sprawling grounds, Makary put forth talking points he has often repeated on his podcast, 'FDA Direct'— a new feature for a commissioner. In a wide-ranging interview, he addressed everything from the agency's staffing changes to his thoughts on Coca-Cola's switch to real sugar. Makary, a gastrointestinal surgeon, took over the FDA just as broad layoffs and a slew of departures of experienced senior staff hit the agency amid changes orchestrated by DOGE, a White House efficiency group that attempted to reform federal government through dramatic cuts. Makary was sworn in on the same day that the cuts took place, April 1. The FDA has since reinstated 'hundreds' of those terminated employees, Makary told CNN on Monday, and the waters have calmed since the layoffs. 'I want the public to know something very clear,' Makary said. 'The FDA is strong, and it will continue to be strong. The trains are running on time,' he said. 'We're going to meet all our targets this year,' he said, referring to the number of drugs and devices the FDA aims to evaluate by January. Such an achievement, if met, would be a relief for a US pharmaceutical industry, that has been watching cautiously as the agency overhauls its regulatory process, promising speedy new pathways for approvals. There has been skepticism. Earlier this year, hundreds of biotech executives had publicly lamented that FDA's leadership on science would be 'irretrievably lost' because of the April staffing losses. While scientists reviewing new drugs and devices were spared from cuts, administrative staff who aid their work were not. Since Makary assumed his post, the FDA also rolled out Elsa, a new artificial intelligence chatbot billed as a tool to help staff speed up clinical reviews and scientific evaluations. But Elsa has made up nonexistent studies and gotten facts wrong, according to six current and former FDA officials who spoke to CNN. Asked about the potential risks of AI-aided review, Makary said it is a work in progress. 'We never want to miss something that could be dangerous,' he said. 'It is a balancing act and we've got to continue to try to do it.' The FDA is also a critical part of Health Secretary Robert F. Kennedy Jr.'s vision to 'Make America Healthy Again' through food policy reforms. This week, the US Department of Health and Human Services, which oversees the FDA, took a first major step toward regulating ultra processed foods b y asking industry and scientific experts for feedback on how to define them. A major tenet of Kennedy's MAHA agenda is to remove artificial ingredients from foods, overhaul prescription drug use, and tackle environmental toxins, all of which he believes are driving chronic illness among American children. Speaking to CNN, Makary laid out a framework for the FDA's broader food policy plans, including dramatic changes to the federal dietary guidelines, a compass for doctors, schools and families on the foods to eat and avoid. They are 'cleaning house' on the guidelines, Makary said. 'We're going to go bold on this because for too long, people have been confused, they've been misled.' 'We have a public trust epidemic in health care because in part people were lied to about what's healthy and what's not healthy,' he said — an assertion that would be highly disputed by experts who advise on the guidelines every five years. Moreover, the dietary guidelines are not entirely up to Makary and his agency. They'll have to hammer out the final recommendations by December with the US Department of Agriculture, and there has already been friction. Makary is also determined to see an end to what he called 'the 70-year war on natural saturated fat'— a substance, he says, that has 'never been found in any clinical trial to be directly associated with heart disease.' That claim is disputable. While Makary did not elaborate on which types of natural saturated fat have been demonized, as he put it, nutrition experts have said there are still significant and well-established harms to heart health from fats in red and processed meats. In dairy, different saturated fats are thought to have varied levels of risk and benefit. Makary's comments come as major food companies and fast-food chains scramble to position themselves as MAHA allies, promising to remove artificial ingredients and food dyes, and switch out seed oils for Kennedy's favored frying ingredient, beef tallow. Coca-Cola announced last week that it would start offering products with cane sugar rather than high-fructose corn syrup, news that was heralded by President Donald Trump. Experts say that is a marginal change; both are ultimately bad for your health. Asked about Coke's sugar announcement, Makary said, 'There are incremental benefits to the different types of sugar out there' but that 'I think it's a good switch.' There is more to come. The commissioner also said that FDA is 'doing an inventory' of more than 11,000 chemicals that are banned in Europe and other countries, but 'common' in the US food supply. Before coming to the FDA, Makary, a surgeon at Johns Hopkins University, was probably best known for a series of books on flaws in the health care system. He supported lockdowns and masking in the early days of the Covid-19 pandemic, but later became a prominent critic of vaccine requirements and booster shots. He argued in a February 2021 Wall Street Journal op-ed that the US would reach herd immunity by that April; instead, new waves of Covid strains hit the population. Those views did not exactly alienate Makary from the medical establishment or Washington's political world. Three Democratic senators voted to confirm him, making him the only one of President Trump's health nominees to win Democratic votes in this administration. 'The day before my Senate confirmation hearing, I was in the operating room. So this is an entirely different domain for me,' Makary said. Sandee LaMotte contributed to this report.
Associated Press
12 minutes ago
- Associated Press
The Environmental Protection Agency wants to bring back the weed killer dicamba
The Environmental Protection Agency has proposed allowing the weed killer dicamba for genetically engineered soybeans and cotton, two crops that are grown extensively in the United States. This week's recommendation comes after the first Trump administration made the same move, only to have courts block it in 2020 and 2024. This is the first year since 2016 that dicamba has not been allowed to be used on crops, according to Nathan Donley, the environmental health science director at the Center for Biological Diversity, a national conservation nonprofit. Environmental groups say they will once again go to court to try to block it. 'This is an unfortunate roller coaster ride that the country has been in for about 10 years now, and it's just incredibly sad to see our Environmental Protection Agency being hijacked by this administration and facilitating decisions that are objectively going to make our environment less healthy,' Donley said. The EPA said via email that it 'will ensure that farmers have the tools they need to protect crops and provide a healthy and affordable food supply for our country' and the agency is 'confident these products won't cause issues for human health or the environment.' The EPA added that the proposal will be open for public comment for 30 days and included a list of proposed guidelines on the use of the three dicamba-containing products in question. Dicamba is a common weed killer and has been used for over 50 years in the U.S., but it has become more widespread on farms in the past decade, according to data from the EPA and the U.S. Geological Survey. Researchers have been working to better understand the health risks it might pose to humans. A 2020 study in the International Journal of Epidemiology found that dicamba exposure was linked to some cancers, including liver cancer and a type of leukemia affecting the blood and bone marrow. Dicamba can also drift far from its intended targets to kill other plants on neighboring farms and in local ecosystems, posing threats to wild flora and fauna, according to the National Wildlife Federation. An agency can tweak a decision after a court strikes it down, and then dicamba would be approved until a new legal challenge succeeds. Past court rulings on dicamba have taken years, 'leaving many farmers with questions and uncertainty in the middle of the growing season,' National Agricultural Law Center staff attorney Brigit Rollins said in a background summary of dicamba legal cases. ___ Follow Melina Walling on X @MelinaWalling and Bluesky @ ___ The Associated Press' climate and environmental coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at
Newsweek
12 minutes ago
- Newsweek
California Proposes Major Drinking Water Change: What to Know
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A bill introduced in California by state senators Anna Caballero and Alexandra Macedo, a Democrat and Republican, respectively, would give water agencies immunity from civil lawsuits regarding chromium-6 contamination in their supply if they are actively working on plans to address the issue. Caballero argued California Senate Bill 466 is needed so water agencies can concentrate on removing the potentially cancer-causing contaminant from their supply, rather than spending their limited resources on legal cases. Newsweek contacted state Senators Caballero and Macedo for comment on Thursday via telephone and voicemail message outside of regular office hours. Why It Matters Chromium-6 is a known carcinogen, meaning it can cause cancer in humans when inhaled or ingested in certain amounts. During the 1990s, a case against Pacific Gas and Electric over contamination of its water in Hinkley, California, with chromium-6 resulted in a $333 million settlement and formed the basis of the 2000 movie Erin Brockovich. According to the Los Banos Enterprise, a newspaper serving the town of 50,000 in central California, water testing has uncovered chromium-6 levels in the settlement above the legal California limit of 10 parts per billion. What To Know Senate Bill 466 would protect water suppliers from civil lawsuits over chromium-6 in California, provided they are either implementing a state-approved compliance plan to reduce chromium-6 levels from their water or are waiting to see if a proposed plan is approved. However, the powers of state regulators are not impacted. The legislation has been endorsed by the City of Los Banos and passed by the California Senate, and is currently making its way through the California State Assembly. Stock photograph showing water running from a tap. Stock photograph showing water running from a tap. show999/GETTY According to the Los Banos Enterprise, city officials estimate reducing chromium-6 levels in water supplied to the town to the state-regulated level will cost around $65 million, around half its annual budget. Los Banos is expected to submit a compliance plan later in 2025 to the State Water Resources Control Board. If Senate Bill 466 is passed, this would protect water suppliers to the city from civil lawsuits while they work to reduce chromium-6 levels. In 2019, the Environmental Working Group concluded that chromium-6 is in the drinking water consumed by more than 200 million Americans. What People Are Saying Addressing The Fresno Bee, state Senator Caballero said: "The goal of SB 466 is not to block accountability, but to make sure resources go toward fixing the problem — not fighting premature lawsuits while a water system is actively working under state oversight to meet the standard. "This bill strikes the balance between protecting public health and giving water providers the time and tools they need to deliver safe water without diverting funds to litigation when they are already doing everything required by the state to comply." Speaking to non-profit news website CalMatters, Los Banos Mayor Michael Amabile said: "I really don't want to go down as the mayor that quadruples water rates, so I need the help from the state." In a report, California state Senate Judiciary Committee staff wrote: "Immunity from liability tends to strip incentives to act with reasonable care by taking away the consequence of having to pay for any damages caused by doing otherwise." In an opinion piece for the publication The Fresno Bee writer Tad Weber said: "A water department as large as Los Banos cannot be brought into legal jeopardy over an inability to pay for a new treatment system that must go online in mere years. Cleaning out chromium-6 will take some time — and money. "Caballero's bill seeks to be a buffer while still ensuring the state does not lose any enforcement capability. As strange as it is for a senior Democrat in the Legislature to argue for protecting water agencies with contaminated supplies, in this case it makes sense." What Happens Next The California State Assembly is expected to vote on Senate Bill 466 in August.
